Pathophysiology of sodium and water retention in heart failure

Cardiology

Volumn 96, Issue 3-4, 2001, Pages 122-131

  Cadnapaphornchai, Melissa A ^a,b   Gurevich, Andrei K ^a   Weinberger, Howard D ^a   Schrier, Robert W ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Children's Hospital Colorado   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Aquaporins; Arterial underfilling; Heart failure; Renin angiotensin aldosterone system; Sympathetic nervous system

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN; SODIUM; WATER;

ADRENERGIC SYSTEM; ARTICLE; BODY FLUID; ENZYME INHIBITION; HEART FAILURE; HORMONE RELEASE; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RETENTION; TREATMENT PLANNING; UNITED STATES; WATER RETENTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; BODY FLUIDS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NEUROSECRETORY SYSTEMS; RENIN-ANGIOTENSIN SYSTEM; SODIUM; SYMPATHETIC NERVOUS SYSTEM; VASOPRESSINS; WATER INTOXICATION; WATER-ELECTROLYTE IMBALANCE;

EID: 0035701638     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047396     Document Type: Article

References (73)

1. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence
2. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
3. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. Part 1
4. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. Part 2
5. Body fluid volume regulation in health and disease: A unifying hypothesis
6. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis
7. Hormones and hemodynamics in heart failure
8. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity
9. Plasma norepinephrine in congestive heart failure
10. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure
11. Abnormalities in systemic norepinephrine kinetics in human congestive heart failure
12. Elevated plasma noradrenaline concentrations in patients with low-output cardiac failure: Dependence on increased noradrenaline secretion rates
13. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
14. Neurohormonal receptors in the failing heart
15. Adrenergic effects on the biology of the adult mammalian cardiocyte
16. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption
17. Neurogenic regulation of renal tubular sodium reabsorption
18. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
19. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
20. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
21. Effects of beta-blocker therapy on mortality in patients with heart failure: A systematic overview of randomized controlled trials
22. Effects of bucindolol on neurohormonal activation in congestive heart failure
23. Concentration of renin in renal venous blood in patients with chronic heart failure
24. The renin-angiotensin-aldosterone system in congestive heart failure in conscious dogs
25. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
26. Angiotensin II facilitates sympathetic transmission in rat hind limb circulation
27. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts
28. Angiotensin II: A potent regulator of acidification in the rat early proximal convoluted tubule
29. Losartan improves the natriuretic response to ANF in rats with high-output heart failure
30. Effect of captopril on renal function in patients with congestive heart failure
31. Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease
32. Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention
33. The role of renin and aldosterone in the salt retention of edema
34. Pathogenesis of ascites formation: Mechanism of impaired aldosterone escape in cirrhosis
35. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
36. Effects of enalapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
37. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
38. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
39. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
40. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial -the Losartan Heart Failure Survival Study ELITE II
41. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
42. Val-HeFT (Valsartan Heart Failure Trial)
43. Atrial natriuretic peptide elevation in congestive heart failure in the human
44. Atrial natriuretic factor as a marker in congestive heart failure
45. Brain natriuretic peptide as a novel hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide
46. Atrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion
47. Relationship between plasma atrial natriuretic peptide levels and atrial pressure in man
48. Biochemical detection of left-ventricular systolic dysfunction
49. Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteers
50. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat
51. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin, and blood pressure in humans
52. Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells
53. Selective antagonism of hormone induced vasoconstriction by synthetic atrial natriuretic factor in the rat microcirculation
54. Effect of physiological levels of atrial natriuretic peptide on hormone secretion: Inhibition of angiotensin-induced aldosterone secretion and renin release in normal man
55. Atrial natriuretic peptide kinetic studies in patients with cardiac dysfunction
56. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene
57. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
58. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
59. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure
60. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure
61. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure
62. Antidiuretic hormone in congestive heart failure
63. High plasma antidiuretic hormone in patients with cardiac failure: Influence of age
64. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct
65. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus
66. Upregulation of aquaporin-2 water channel expression in chronic heart failure
67. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in the collecting duct
68. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure
69. Urinary excretion of aquaporin-2 in the rat is mediated by a vasopressin-dependent apical pathway
70. Urinary excretion of aquaporin-2 water channel protein in human and rat
71. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
72. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
73. Chronic oral endothelin type A receptor antagonism in experimental heart failure